Antibiotic Co-Therapy Targeting Both the Oral Cavity & Gut
Respiratory infections are the primary diagnosis of antibiotic use. The use of antibiotics kills not only pathogens but also protective microbiota in the oral cavity and the gut, causing dysbiosis. Dysbiosis condition increases susceptibility to disease and causes recurrent infections. The frequent use of antibiotics is also associated with various side effects such as diarrhea.
ImmuneBioflora is a new type of antibiotic co-therapy that reduces the respiratory symptoms and the side effects of antibiotics during antibiotic use. Further, after the antibiotic use restores a protective oral & gut microbiota.
- New era in antibiotic co-therapy supporting both the oral and gut microbiota
- Exclusive combination of K12 and LGG bacteria strains
- Premium probiotic protection acting in two different levels
- Optimized mucoadhesive properties and longer disintegration to ensure maximum colonization
Premium Probiotic Protection
Our exclusive strain combination acts on two different levels.
1st Level The Oral Cavity
Reducing respiratory symptoms & restoring the oral cavity microbiota: Producing bacteriocins and stimulating the local secretion of anti-viral antibodies (sIgA) and cytokines (INF-y) at the main entrance point of pathogens (viruses and bacteria).
2nd Level The Gut
Restoring the gut microbiota: Colonizing the gut to improve the gastrointestinal function and reducing the antibiotic-associated diarrhea (AAD).
ImmuneBioflora®
- Restoring the protective microbiota of the oral cavity and gut after antibiotic intake
- Decreasing antibiotic-associated diarrhea
- Reducing respiratory symptoms during antibiotic therapy